GLP-1 receptor agonists have direct effects on glucose metabolism and lipid profiles that operate independently of body weight changes
This distinction is particularly relevant for clinical practice, as REWIND demonstrated benefits in patients at moderate cardiovascular risk without previous events
We answer these questions before anything gets prescribed: We build a strategy around the individual, the goal, the full clinical picture, and whether the approach is effective
designed a series of bispecific killer-cell-bridging antibodies (NKAB-EGFR and NKAB-ERBB2) that link NKG2D-CAR NK cells to EGFR or ERBB2, enabling ligand-independent, precision targeting [80]
What is the cost of compounded tirzepatide
Pharmacovigilance-based drug repurposing: the search for inverse signals via openvigil identifies putative drugs against viral respiratory infections